A method for the treatment of a disease of the airways accompanied by increased production of mucus, wherein the disease is selected from chronic bronchitis, chronic obstructive bronchitis (COPD), asthma, bronchiectasis, allergic or non-allergic rhinitis or sinusitis, cystic fibrosis, α1-antitrypsin deficiency, coughs, pulmonary emphysema, pulmonary fibrosis and hyperreactive airways, comprising administering to a patient a therapeutically effective amount of a compound of formula (I)
- wherein
- Ra denotes a phenyl or 1-phenylethyl group, wherein the phenyl nucleus is substituted in each case by the groups R1 to R3, wherein
- R1 and R2 which may be identical or different, denote hydrogen or
- a group selected from among
- F, Cl, Br, I, OCH2F, OCHF2, OCF3, CH2F, CHF2, CF3, CN, NO2, NH2 and OH,
- or
- a group selected from among
- C1-4-alkyl, C1-4-alkyl-O, C2-3-alkenyl, C2-3-alkynyl,
- phenyl, phenyl-O, phenyl-C1-3-alkyl, phenyl-C1-3-alkyl-O, heteroaryl, heteroaryl-O, heteroaryl-C1-3-alkyl, heteroaryl-C1-3-alkyl-O, while the above-mentioned phenyl groups are mono- or disubstituted by groups R5,
- and
- R3 denotes hydrogen,
- or
- a group selected from among
- F, Cl, Br and CH3,
- Rb denotes hydrogen, or a group, optionally substituted, selected from among C1-6-alkyl, C3-6-cycloalkyl- and C3-6-cycloalkyl-C1-3-alkyl,
- Rc denotes hydrogen, or an optionally substituted group selected from among C1-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-3-alkyl, C1-6-alkyl-CO, C3-6-cycloalkyl-CO, C3-6-cycloalkyl-C1-3-alkyl-CO, C1-6-alkyl-SO2, C3-6-cycloalkyl-SO2, C3-6-cycloalkyl-C1-3-alkyl-SO2, phenyl-CO— and phenyl-SO2,
- Rd denotes hydrogen or
- a group selected from among
- F, Cl, Br, I, OH, C1-4-alkyl, C1-4-alkyl-O, C1-2-alkyl-O substituted by 1 to 3 fluorine atoms, C3-7-cycloalkyl-O, C3-7-cycloalkyl-C1-4-alkyl-O, tetrahydrofuran-3-yl-O, tetrahydropyran-3-yl-O, tetrahydro-pyran-4-yl-O, tetrahydrofuranyl-C1-4-alkyl-O— and tetrahydropyranyl-C1-4-alkyl-O,
- or
- R4—C1-4-alkyl, while the linking of the groups R4 may take place via each C atom of the alkyl group,
- or
- R4—C2-4-alkyl-O, wherein the group R4 is separated from the oxygen atom by at least 2 C atoms,
- or
- a group selected from among
- pyrrolidin-2-yl-C1-4-alkyl-O, pyrrolidin-3-yl-C1-4-alkyl-O, piperidin-2-yl-C1-4-alkyl-O, piperidin-3-yl-C1-4-alkyl-O, piperidin-4-yl-C1-4-alkyl-O, azepan-2-yl-C1-4-alkyl-O, azepan-3-yl-C1-4-alkyl-O, azepan-4-yl-C1-4-alkyl-O, morpholin-2-yl-C1-4-alkyl-O, morpholin-3-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-pyrrolidin-2-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-pyrrolidin-3-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-piperidin-2-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-piperidin-3-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-piperidin-4-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-azepan-2-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-azepan-3-yl-C1-4-alkyl-O, 1-(C1-3-alkyl)-azepan-4-yl-C1-4-alkyl-O, 4-(C1-3-alkyl)-morpholin-2-yl-C1-4-alkyl-O— and 4-(C1-3-alkyl)-morpholin-3-yl-C1-4-alkyl-O,
- while
- R4 denotes a group, which may be identical or different, selected from among OH, C1-3-alkyl-O, C3-6-cycloalkyl-O, NH2, C1-3-alkyl-NH, (C1-3-alkyl)2N, (2-methoxyethyl)2N, pyrrolidin-1-yl, piperidin-1-yl, azepan-1-yl, morpholin-4-yl, 1,4-oxazepan-4-yl, 2-oxa-5-aza-bicyclo[2,2,1]hept-5-yl, 3-oxa-8-aza-bicyclo[3.2.1]oct-8-yl, 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl, piperazin-1-yl, 4-(C1-3-alkyl)-piperazin-1-yl, 1,4-diazepan-1-yl, 4-(C1-3-alkyl)-1,4-diazepan-1-yl, HCO—NH, C1-4-alkyl-CO—NH, C1-3-alkyl-O—C1-3-alkyl-CO—NH, C1-4-alkyl-O—CO—NH, H2NCONH, C1-3-alkyl-NH—CO—NH, (C1-3-alkyl)2N—CONH, pyrrolidin-1-yl-CO—NH, piperidin-1-yl-CO—NH , piperazin-1-yl-CO—NH, 4-(C1-3-alkyl)-piperazin-1-yl-CO—NH , morpholin-4-yl-CO—NH— and C1-4-alkyl-SO2—NH,
- while the pyrrolidinyl, piperidinyl, azepan-1-yl, piperazinyl, 1,4-diazepan-1-yl, morpholinyl- and 1,4-oxazepan-4-yl groups mentioned above in the definition of the group Rd may each additionally be substituted by one or two C1-3-alkyl groups,
- and
- wherein the above-mentioned phenyl groups are mono- or disubstituted by groups R5, wherein
- R5 denotes hydrogen, or
- a group, which may be identical or different, selected from among
- F, Cl, Br, I, OH, CN, C1-3-alkyl, C1-3-alkyl-O, CHF2, CF3, —O—CHF2 and —O—CF3,
- and
- unless stated otherwise, the above-mentioned alkyl groups may be straight-chain or branched,
- A denotes a C2-alkylene group
- wherein the C2-alkylene group may be 1-, 2-, 3- or 4-substituted by a group R6,
- and
- R6 which may be identical or different, denotes hydrogen, or
- a group selected from among OH, C1-C4-alkyl and —O—C1-C4-alkyl
- optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, or a pharmacologically acceptable acid addition salt thereof.